NGS | GenomeWeb


Researchers at the Hartwig Medical Foundation have launched a clinical trial that seeks to match tumor biomarkers with experimental and off-label drugs.

The next-generation sequencing-based test is designed to detect bacteria and viruses in blood samples from patients with suspected infections, especially immunocompromised patients.

The company will use its new software-as-service platform OncoKDM to generate genomic reports to match breast cancer patients to clinical trials.

Following this agreement, LifeCodexx's PrenaTest is now available in more than 40 countries throughout Europe and the Middle East. 

The new partners plan to develop apps for Helix's DNA sequencing platform related to ancestry, reproductive health, and food and drink. 

The court ordered the molecular diagnostic company to stop offering the Fetalis test it started offering in Germany this summer, which is based on Ariosa's technology.

Under the terms of the agreement, Q2 Solutions will develop companion diagnostics on Illumina's MiSeqDx instrument.

Through Navican, patients at Intermountain can get tested on an internally developed NGS platform that gauges a range of actionable genes implicated in cancer. 

The company plans to raise $25 million in a Series B financing round. It is also working on a two-color chemistry and aims to develop an instrument for clinical applications.

Under the partnership, Myriad will be ION's preferred partner for providing hereditary testing to its member practices. 


In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.